MedTrace Logo

Salt Supplementation in Gitelman Syndrome

NCT04995627 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2024-11-21

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of salt (NaCl) supplementation on serum potassium and clinical signs and symptoms in patients with Gitelman syndrome.

Conditions

  • Gitelman Syndrome

Interventions

DIETARY_SUPPLEMENT

Salt (NaCl)

12 grams of salt (NaCl) per day

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Dutch Kidney Foundation

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Tom Nijenhuis, MD PhD · Radboud University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-19
Primary Completion
2024-09-01
Completion
2024-09-01

Countries

  • Italy
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04995627 on ClinicalTrials.gov